STEP-4 (N=803) demonstrated that discontinuing semaglutide after 20 weeks led to regain of approximately two-thirds of lost weight within one year, underscoring that GLP-1 therapy requires ongoing use
Online, some doctors say the drug is on back order through December
Liraglutide also slows gastric emptying, reduces appetite, and promotes weight loss, making it effective for treating type 2 diabetes and obesity while lowering cardiovascular risk
The utility for each health state in this study was as recommended in a review of utility values for type 2 diabetes and its complications [22]
Although the FDA has no requirement for the investigational drug to show superiority to placebo, ELIXA is designed to demonstrate that lixisenatide reduces cardiovascular morbidity and mortality in patients with type 2 diabetes who have recently experienced an acute coronary syndrome event
The medications, dosing protocols, and lab monitoring are identical whether visits happen in person or by video
.png)
